Details for New Drug Application (NDA): 203491

✉ Email this page to a colleague

NDA 203491 describes ILEVRO, which is a drug marketed by Harrow Eye and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ILEVRO profile page.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.

Summary for 203491

Tradename:	ILEVRO
Applicant:	Harrow Eye
Ingredient:	nepafenac
Patents:	3

Pharmacology for NDA: 203491

Mechanism of Action	Cyclooxygenase Inhibitors

Suppliers and Packaging for NDA: 203491

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491	NDA	Novartis Pharmaceuticals Corporation	0078-0743	0078-0743-03	1 BOTTLE in 1 CARTON (0078-0743-03) / 3 mL in 1 BOTTLE
ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491	NDA	Novartis Pharmaceuticals Corporation	0078-0743	0078-0743-96	1 BOTTLE in 1 CARTON (0078-0743-96) / .8 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SUSPENSION/DROPS;OPHTHALMIC			Strength	0.3%
Approval Date:	Oct 16, 2012	TE:		RLD:	Yes
Patent:	⤷ Subscribe	Patent Expiration:	Jun 8, 2024	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Subscribe	Patent Expiration:	Mar 31, 2032	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Subscribe	Patent Expiration:	Dec 1, 2030	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 203491

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012	⤷ Subscribe	⤷ Subscribe
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012	⤷ Subscribe	⤷ Subscribe
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.